Elena Crehuá-Gaudiza, Saioa Vicente Santamaría, Marina Álvarez Beltrán, Carmen Martín Fernández, Carlos Tutau Gómez, Inés Loverdos Eseverri, Ruth García Romero, Encarni Torcuato Rubio, Rodrigo Del Brío Castillo, María Garriga García, Celia Gascón Galindo, José Ramón Gutiérrez Martínez, Ana María Castro Millán, Sara Sierra San Nicolás, Pilar Ortiz Pérez, Camila García Volpe, Enrique Salcedo Lobato, Agustín De La Mano Hernández, Sara María Fernández González, Ana Reyes Domínguez, Luis Peña-Quintana, David González Jiménez
{"title":"囊性纤维化调节剂治疗对血清脂溶性维生素水平的影响。","authors":"Elena Crehuá-Gaudiza, Saioa Vicente Santamaría, Marina Álvarez Beltrán, Carmen Martín Fernández, Carlos Tutau Gómez, Inés Loverdos Eseverri, Ruth García Romero, Encarni Torcuato Rubio, Rodrigo Del Brío Castillo, María Garriga García, Celia Gascón Galindo, José Ramón Gutiérrez Martínez, Ana María Castro Millán, Sara Sierra San Nicolás, Pilar Ortiz Pérez, Camila García Volpe, Enrique Salcedo Lobato, Agustín De La Mano Hernández, Sara María Fernández González, Ana Reyes Domínguez, Luis Peña-Quintana, David González Jiménez","doi":"10.1002/jpr3.70007","DOIUrl":null,"url":null,"abstract":"<p><p>This is a prospective, multicenter study of a cohort of 224 cystic fibrosis (CF) patients treated with CF transmembrane conductance regulator (CFTR) modulators (CFTRm). Our aim was to prospectively analyze the effect of CFTRm treatment on fat-soluble vitamin serum levels. Demographic and clinical data were recorded, and fat-soluble vitamin levels were analyzed at baseline, and at 6 and 12 months after starting treatment. Two groups were analyzed separately: patients receiving dual therapy lumacaftor/ivacaftor or tezacaftor/ivacaftor (Lum/Tez+Iva), and those on triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI). We found that treatment with ETI produced a significant increase in vitamin D and A levels within the first 6 months, which was maintained at 12 months. However, with dual therapy, we observed an increase only in vitamin A levels within the first 6 months, which was not maintained at 12 months. No differences were found in vitamin E serum levels between the groups.</p>","PeriodicalId":501015,"journal":{"name":"JPGN reports","volume":"6 2","pages":"146-152"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078071/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of cystic fibrosis modulator therapies on serum levels of fat-soluble vitamins.\",\"authors\":\"Elena Crehuá-Gaudiza, Saioa Vicente Santamaría, Marina Álvarez Beltrán, Carmen Martín Fernández, Carlos Tutau Gómez, Inés Loverdos Eseverri, Ruth García Romero, Encarni Torcuato Rubio, Rodrigo Del Brío Castillo, María Garriga García, Celia Gascón Galindo, José Ramón Gutiérrez Martínez, Ana María Castro Millán, Sara Sierra San Nicolás, Pilar Ortiz Pérez, Camila García Volpe, Enrique Salcedo Lobato, Agustín De La Mano Hernández, Sara María Fernández González, Ana Reyes Domínguez, Luis Peña-Quintana, David González Jiménez\",\"doi\":\"10.1002/jpr3.70007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This is a prospective, multicenter study of a cohort of 224 cystic fibrosis (CF) patients treated with CF transmembrane conductance regulator (CFTR) modulators (CFTRm). Our aim was to prospectively analyze the effect of CFTRm treatment on fat-soluble vitamin serum levels. Demographic and clinical data were recorded, and fat-soluble vitamin levels were analyzed at baseline, and at 6 and 12 months after starting treatment. Two groups were analyzed separately: patients receiving dual therapy lumacaftor/ivacaftor or tezacaftor/ivacaftor (Lum/Tez+Iva), and those on triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI). We found that treatment with ETI produced a significant increase in vitamin D and A levels within the first 6 months, which was maintained at 12 months. However, with dual therapy, we observed an increase only in vitamin A levels within the first 6 months, which was not maintained at 12 months. No differences were found in vitamin E serum levels between the groups.</p>\",\"PeriodicalId\":501015,\"journal\":{\"name\":\"JPGN reports\",\"volume\":\"6 2\",\"pages\":\"146-152\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078071/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JPGN reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/jpr3.70007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JPGN reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/jpr3.70007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Effect of cystic fibrosis modulator therapies on serum levels of fat-soluble vitamins.
This is a prospective, multicenter study of a cohort of 224 cystic fibrosis (CF) patients treated with CF transmembrane conductance regulator (CFTR) modulators (CFTRm). Our aim was to prospectively analyze the effect of CFTRm treatment on fat-soluble vitamin serum levels. Demographic and clinical data were recorded, and fat-soluble vitamin levels were analyzed at baseline, and at 6 and 12 months after starting treatment. Two groups were analyzed separately: patients receiving dual therapy lumacaftor/ivacaftor or tezacaftor/ivacaftor (Lum/Tez+Iva), and those on triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI). We found that treatment with ETI produced a significant increase in vitamin D and A levels within the first 6 months, which was maintained at 12 months. However, with dual therapy, we observed an increase only in vitamin A levels within the first 6 months, which was not maintained at 12 months. No differences were found in vitamin E serum levels between the groups.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
